clinicaltrials | On the topic of immune escape: Gauteng, the province where the Omicron cluster was detected, has just come out of heavy Delta wave. This suggests that the antibodies binding to Delta might not do that much for Omicron.
This is also quite possibly the reason for Omicron being discovered there – researchers encountered
an unexpected and unexplained uptick in Covid numbers, prompting them to look a bit harder. Of course luck favours the prepared – the research teams there are capable, in possession of good sequencing kits and know how to use them.
I would not be surprised if Omicron arose somewhere else completely, and just got detected in Gauteng.
The vast number new of mutations could be explained by an unknown population outside RSA, whether nearby in Zimbabwe or at the other ends of Africa be it in Senegal or Egypt.
This does suggest that blocking flights from RSA might already be too late. This is not to say that quarantining international flyers is a bad thing – if I were in charge that would be the case for any international arival anywhere. Pets have always been quarantined – if your dog has to do it, you should too.
Finally I have a theory why the WHO is so reluctant to ban international air travel: WHO staff are probably among the most frequent of fliers – one day in Geneva at a conference, the next day in Canada to lobby for funding and the next week in the DRC to worry about Ebola. This means that blocking flights is unthinkable for them, even if it is a sensible course of action.
| Row | Saved | Status | Study Title | Conditions | Interventions | Locations |
|---|---|---|---|---|---|---|
| 1 | Recruiting | COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults |
|
|
| |
| 2 | Active, not recruiting | BCG Vaccination for Healthcare Workers in COVID-19 Pandemic |
|
|
| |
| 3 | Recruiting | A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection |
|
|
| |
| 4 | Not yet recruiting | A Study of Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases |
|
|
| |
| 5 | Recruiting | Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents |
|
|
| |
| 6 | Not yet recruiting | A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 |
|
|
| |
| 7 | Recruiting | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals |
|
|
| |
| 8 | Active, not recruiting | A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants |
|
|
| |
| 9 | Recruiting | A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults |
|
|
| |
| 10 | Active, not recruiting | Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older |
|
|
|
0 comments:
Post a Comment